HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility

ConclusionAlthough this polymorphism did not demonstrate potential as a prognostic marker, it may be a suitable susceptibility marker for BC.
Source: Journal of Clinical Laboratory Analysis - Category: Laboratory Medicine Authors: Tags: RESEARCH ARTICLE Source Type: research

Related Links:

Conditions:   Breast Cancer;   HR+/HER2-negative Breast Cancer;   Metastasis Intervention:   Drug: Fulvestrant + palbociclib Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: In this study, PABC showed lower expression of ER/PR, higher overexpression of HER2, fewer luminal A subtype, and more TNBC subtype compared to YBC. PABC had worse BCSS, especially luminal B subtype, compared to YBC.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThis work shows that PK-toxicity modeling provides insight into how the severity of key adverse events evolves over time and highlights the potential use to support decision making in drug development.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
AbstractImmunology and immunotherapy of cancer is an expanding field in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly considered a novel hallmark of cancer. Translational research in this topic has revealed targets that can be modulated in the clinical setting with new compounds and strategies. Like most of the tumors, breast cancer is considered a complex and heterogeneous disease in which host immune responses have been also recently demonstrated of critical relevance. T infiltrating lymphocyte measurement is suggeste...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases. Exp Ther Med. 2018 Jun;15(6):5475-5480 Authors: Lv Z, Liu M, Shen J, Xiang D, Ma Y, Ji Y Abstract Interleukin-10 (IL-10), interleukin-17A (IL-17A) and transforming growth factor α (TGF-α) have been implicated in the progression of breast cancer. However, the diagnostic and prognostic roles of these cytokines in ductal carcinoma remain unclear. The present study therefore aimed to determine the serum levels of IL-10, IL-17 and TGF-α in subj...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
AbstractBreast cancer is a major cause of cancer-related death in women worldwide. miRNAs are new players of breast tumorigenesis, used as diagnostic and prognostic biomarkers. Among various miRNAs, miR-126 has been proposed to have a tumor suppressive role in HER2 positive cancer. However, to have a better understanding of its role, further validation is required. The aim of this study was evaluating miR-126 expression level in breast cancer tissues and investigating its potential association with HER2, estrogen and progesterone receptors. miR-126 expression level was measured in 108 specimens including 78 malignant and 3...
Source: Indian Journal of Clinical Biochemistry - Category: Biochemistry Source Type: research
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
In conclusion, the coadministration of both drugs in patients with this type of cancer could contribute to the improvement of their prognosis and reduce the adverse effects of therapy because the applied Tz doses would be lower due to the adjuvant effect of RA. PMID: 29899874 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Santonja A, Sánchez-Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, Antolín S, Jerez JM, de la Haba J, de Luque V, Fernández-De Sousa CE, Vicioso L, Plata Y, Ramírez-Tortosa CL, Álvarez M, Llácer C, Zarcos-Pedrinaci I, Carrasco E, Caballero R, Martín M, Alba E Abstract Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypes by identifying any ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
(MedPage Today) -- In contrast with FDA, Britain's cost watchdog says drug may not offer'meaningful'benefit
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: Brazil Health | Breast Cancer | Cancer | Cancer & Oncology | Chia | Genetics | HER2 | Hormones | Laboratory Medicine | Study | Women